The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.

Front Pharmacol · 2026 · PMC13218857 · PMID 42222145

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

close to significancep = 0.1so close (0.05 < p ≤ 0.1)

The prior treatment with caplacizumab was also close to significance in terms of relapse risk (15 vs. 24, p = 0.1).

also in 2,130 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.